BPR1K871 is a potent and selective dual FLT3/AURKA inhibitor with IC50s of 19 nM and 22 nM for FLT3 and AURKA, respectively, acts as a preclinical development candidate for anti-cancer therapy.
IC50&Target
IC50: 19 nM (FLT3), 22 nM (AURKA)
体外研究
BPR1K871 shows potent anti-proliferative activities in MOLM-13 and MV4-11 AML cells with an EC50 of ~ 5 nM.
体内研究
BPR1K871 is a multi-kinase inhibitor for the treatment of acute myeloid leukemia (AML) and solid tumors.
分子式
C25H28ClN7O2S
分子量
526.05
CAS号
2443767-35-7
运输条件
Room temperature in continental US; may vary elsewhere.